A new high protein-to-energy enteral formula with a whey protein hydrolysate to achieve protein targets in critically ill patients: a prospective observational tolerability study
Open Access
- 24 June 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 76 (3) , 419-427
Abstract
Objectives: Current guidelines and expert recommendations stress the need to implement enteral feeds with a higher protein-to-energy ratio to meet protein requirements as recommended while avoiding gastrointestinal side effects and energy overfeeding in ICU patients. Materials and methods: Prospective tolerability study in 18 critically ill patients with a high protein formula (high protein-to-energy (HP:E) formula = Fresubin® Intensive; HPG) compared to a contemporary matched conventional therapy group (CTG). The primary outcome was GI intolerance defined as ≥300 ml daily gastric residual volume (GRV), vomiting, or diarrhea on days 1 and 2. Secondary outcomes were the percentage of patients reaching their protein target on day 4 and overall protein intake. Results: Groups were comparable regarding demographic characteristics, disease severity, organ failures, mechanical ventilation, and NUTRIC score at baseline. Eighteen patients completed the 4-day feeding period. The number of events of GRV of ≥300 ml/day was equal in both groups (33.3%). The incidence of diarrhea and vomiting was low in the HPG (two patients concerned). EN did not need to be discontinued due to intolerance in any group. Seventy-two percent of patients reached protein targets ≥1.3 g/kgBW/d within 4 days after initiation of enteral feeding, which was superior to the CTG (33%). Post-hoc testing showed group differences of protein intake between HPG and CTG were significant at t = 72 h and t = 96 h. Energy targets were met in both groups. Conclusion: The HP:E formula containing 33% whey protein hydrolysate is well tolerated in this tolerability study. Due to the HP:E ratio protein targets can be reached faster. Larger randomized trials are needed to confirm preliminary results. Trial registration: ClinicalTrials.gov Identifier: NCT02678325. Registered 2 May 2016.Keywords
Funding Information
- Fresenius Kabi, Bad Homburg, Germany contributed to the expenditures of the study by providing the HP:E formula (Fresubin® Intensive, Fresenius Kabi, Bad Homburg, Germany).
This publication has 50 references indexed in Scilit:
- Acute Skeletal Muscle Wasting in Critical IllnessJAMA, 2013
- Milk protein for improved metabolic health: a review of the evidenceNutrition & Metabolism, 2013
- The Impact of Implementation of a Nutrition Support Algorithm on Nutrition Care Outcomes in an Intensive Care UnitNutrition in Clinical Practice, 2012
- Appropriate protein provision in critical illness: a systematic and narrative reviewThe American Journal of Clinical Nutrition, 2012
- Optimal Protein and Energy Nutrition Decreases Mortality in Mechanically Ventilated, Critically Ill PatientsJournal of Parenteral and Enteral Nutrition, 2011
- Evidence that protein requirements have been significantly underestimatedCurrent Opinion in Clinical Nutrition and Metabolic Care, 2010
- Effects of inflammation and/or inactivity on the need for dietary proteinCurrent Opinion in Clinical Nutrition and Metabolic Care, 2009
- Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young menJournal of Applied Physiology, 2009
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Whole-Body Protein Turnover in Humans—Past, Present, and FutureAnnual Review of Nutrition, 1995